CSF1R and pancreatic neoplasm: Targeting TAMs by inhibiting colony-stimulating factor-1 receptor (CSF1R) or chemokine (C–C motif) receptor 2 (CCR2) decreases the number of pancreatic tumor cells and improves chemotherapeutic efficacy, inhibits metastasis and increases anti-tumoral T cell responses in vivo [236].